A Phase I Study of the First-in-Class Anti-Mitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies

PURPOSE: The lipoate derivative CPI-613 is a first-in-class agent that targets mitochondrial metabolism. This study determined the effects of CPI-613 on mitochondrial function and defined the maximally tolerated dose (MTD), pharmacokinetics (PKs), and safety in patients with relapsed or refractory h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pardee, Timothy S., Lee, King, Luddy, John, Maturo, Claudia, Rodriguez, Robert, Isom, Scott, Miller, Lance D., Stadelman, Kristin M., Levitan, Denise, Hurd, David, Ellis, Leslie R., Harrelson, Robin, Manuel, Megan, Dralle, Sarah, Lyerly, Susan, Powell, Bayard L
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199870/
https://ncbi.nlm.nih.gov/pubmed/25165100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados